Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial

OncoImmunology

Volumn 4, Issue 4, 2015, Pages

  Schmitz Winnenthal, Friedrich H ^a   Hohmann, Nicolas ^a   Niethammer, Andreas G ^b   Friedrich, Tobias ^a   Lubenau, Heinz ^c   Springer, Marco ^c   Breiner, Klaus M ^b   Mikus, Gerd ^a   Weitz, Jürgen ^a   Ulrich, Alexis ^a   Buechler, Markus W ^a   Pianka, Frank ^a   Klaiber, Ulla ^a   Diener, Markus ^a   Leowardi, Christine ^a   Schimmack, Simon ^a   Sisic, Leila ^a   Keller, Anne Valerie ^a   Koc, Ruhan ^a   Springfeld, Christoph ^d   Knebel, Philipp ^a   Schmidt, Thomas ^a   Ge, Yingzi ^d   Bucur, Mariana ^d   Stamova, Slava ^d   Podola, Lilli ^d   Haefeli, Walter E ^a   Grenacher, Lars ^a   Beckhove, Philipp ^d   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b VAXIMM AG   (Switzerland)

^c Vaximm   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anti angiogenic treatment; Cancer immunotherapy; Oral vaccination; Pancreatic cancer; VEGFR2

Indexed keywords

COLLAGEN TYPE 4; GAMMA INTERFERON; PLACEBO; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VXMO1;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER STAGING; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTOPENIA; MALE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SALMONELLA; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

EID: 84954342124     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2014.1001217     Document Type: Article

References (32)

1. Xiang R, Luo Y, Niethammer AG, Reisfeld RA. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 2008; 222:117-28; PMID:18363997; http://dx. doi. org/10. 1111/j. 1600-065X. 2008. 00613. x
2. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and metaanalysis of randomised controlled trials. Vaccine 2007; 25:7848-57; PMID:17928109; http://dx. doi. org/ 10. 1016/j. vaccine. 2007. 08. 027
3. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013; 153:13-9; PMID:23172303; http://dx. doi. org/ 10. 1093/jb/mvs136
4. Bruce D, Tan PH. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? Cell Commun Adhes 2011; 18:85-103; PMID:22017472; http://dx. doi. org/10. 3109/15419061. 2011. 619673
5. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012; 12:699-709; PMID:23001349; http://dx. doi. org/10. 1038/ nrc3366
6. Spratlin J. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 2011; 13:97-102; PMID:21222245; http://dx. doi. org/10. 1007/s11912-010-0149-5
7. Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M et al. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012; 12:361; PMID:22906006; http://dx. doi. org/10. 1186/ 1471-2407-12-361
8. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8:1369-75; PMID:12415261; http://dx. doi. org/ 10. 1038/nm1202-794
9. Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012; 10:156; PMID:22862954; http://dx. doi. org/10. 1186/1479-5876-10-156
10. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58; PMID:18323851; http://dx. doi. org/10. 1038/nri2274
11. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, Juenger S, Vlodavsky I, Khazaie K, Jaeger D et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311-21; PMID:19809157
12. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6:327-38; PMID:19483739; http://dx. doi. org/10. 1038/nrclinonc. 2009. 63
13. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7:475-85; PMID:17522716; http://dx. doi. org/10. 1038/nrc2152
14. Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, Friess H. Pancreatic cancer microenvironment. Int J Cancer 2007; 121:699-705; PMID:17534898; http://dx. doi. org/10. 1002/ijc. 22871
15. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24:589-602; PMID:24209604; http://dx. doi. org/ 10. 1016/j. ccr. 2013. 09. 014
16. Schmitz-Winnenthal FH, Volk C, Z'Graggen K, Galindo L, Nummer D, Ziouta Y, Bucur M, Weitz J, Schirrmacher V, Büchler MW, Beckhove P. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005; 65:10079-87; PMID:16267034; http://dx. doi. org/10. 1158/0008-5472. CAN-05-1098
17. Sommerfeldt N, Schutz F, Sohn C, Forster J, Schirrmacher V, Beckhove P. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006; 66:8258-65; PMID:16912206; http://dx. doi. org/ 10. 1158/0008-5472. CAN-05-4201
18. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012; 30:1835-41; PMID:22529253; http://dx. doi. org/10. 1200/JCO. 2011. 40. 2271
19. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7:452-8; PMID:11283672; http://dx. doi. org/10. 1038/ 86523
20. Beckhove P, Feuerer M, Dolenc M, Schuetz F, Choi C, Sommerfeldt N, Schwendemann J, Ehlert K, Altevogt P, Bastert G et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 2004; 114:67-76; PMID:15232613; http://dx. doi. org/ 10. 1172/JCI200420278
21. Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, Vlodavsky I, Sommerfeldt N, Sinn HP, Kühnle MC et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009; 69:8420-8; PMID:19843863; http://dx. doi. org/10. 1158/0008-5472. CAN-09-1627
22. Schuetz F, Ehlert K, Ge Y, Schneeweiss A, Rom J, Inzkirweli N, Sohn C, Schirrmacher V, Beckhove P. Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunol Immunother 2009; 58:887-900; PMID:18998129; http://dx. doi. org/10. 1007/s00262-008-0605-3
23. Schirrmacher V, Feuerer M, Fournier P, Ahlert T, Umansky V, Beckhove P. T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 2003; 9:526-34; PMID:14659467; http://dx. doi. org/10. 1016/j. molmed. 2003. 10. 001
24. Sommerfeldt N, Beckhove P, Ge Y, Schutz F, Choi C, Bucur M, Domschke C, Sohn C, Schneeweis A, Rom J et al. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 2006; 66:7716-23; PMID:16885374; http://dx. doi. org/ 10. 1158/0008-5472. CAN-05-2363
25. Nummer D, Suri-Payer E, Schmitz-Winnenthal H, Bonertz A, Galindo L, Antolovich D, Koch M, Büchler M, Weitz J, Schirrmacher V et al. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 2007; 99:1188-99; PMID:17652277; http://dx. doi. org/10. 1093/jnci/djm064
26. Meijerink MR, van Cruijsen H, Hoekman K, Kater M, van Schaik C, van Waesberghe JH, Giaccone G, Manoliu RA. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 2007; 17:1700-13; PMID:17072618; http://dx. doi. org/10. 1007/s00330-006-0425-9
27. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27:2231-7; PMID:19307500; http://dx. doi. org/ 10. 1200/JCO. 2008. 20. 0238
28. Okamoto I, Arao T, Miyazaki M, Satoh T, Okamoto K, Tsunoda T, Nishio K, Nakagawa K. Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci 2012; 103:2135-8; PMID:22957712; http://dx. doi. org/10. 1111/cas. 12014
29. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012; 61:353-62; PMID:21915801; http://dx. doi. org/ 10. 1007/s00262-011-1106-3
30. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM. "MIATA"-minimal information about T cell assays. Immunity 2009; 31:527-8; PMID:19833080; http://dx. doi. org/10. 1016/j. immuni. 2009. 09. 007
31. Kim SH, Lee JM, Gupta SN, Han JK, Choi BI. Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. J Magn Reson Imaging 2014; 40:730-7; PMID:24307571; http://dx. doi. org/10. 1002/jmri. 24387
32. WeberMA, HenzeM, Tuttenberg J, Stieltjes B, Meissner M, Zimmer F, Burkholder I, Kroll A, Combs SE, Vogt-Schaden M et al. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol 2010; 45:755-68; PMID:20829706; http://dx. doi. org/10. 1097/RLI. 0b013e3181ec9db0